

09/626, 122

FILE 'HOME' ENTERED AT 11:18:17 ON 28 NOV 2001

=> file biosis medline caplus wpids uspatfull  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.15	0.15

FULL ESTIMATED COST

FILE 'BIOSIS' ENTERED AT 11:18:40 ON 28 NOV 2001  
COPYRIGHT (C) 2001 BIOSIS(R)

FILE 'MEDLINE' ENTERED AT 11:18:40 ON 28 NOV 2001

FILE 'CAPLUS' ENTERED AT 11:18:40 ON 28 NOV 2001  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 11:18:40 ON 28 NOV 2001  
COPYRIGHT (C) 2001 DERWENT INFORMATION LTD

FILE 'USPATFULL' ENTERED AT 11:18:40 ON 28 NOV 2001  
CA INDEXING COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

\*\*\* YOU HAVE NEW MAIL \*\*\*

=> s recombinant expression construct and plant cell  
L1 14 RECOMBINANT EXPRESSION CONSTRUCT AND PLANT CELL

=> s l1 and lysosomal  
L2 2 L1 AND LYSSOSOMAL

=> d l2 bib abs 1-2

L2 ANSWER 1 OF 2 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD  
AN 1997-202248 [18] WPIDS  
DNN N1997-167118 DNC C1997-064741  
TI Production of enzymatically active (modified) **lysosomal** enzyme  
in transgenic plants - useful in treatment of **lysosomal** storage  
disorders.  
DC B04 C06 D16 P13  
IN CRAMER, C L; OISHI, K K; RADIN, D N; WEISSENBERN, D L  
PA (CROP-N) CROPTech DEV CORP; (VIRG) VIRGINIA TECH INTELLECTUAL PTY INC;  
(VIRG) VIRGINIA TECH INTELLECTUAL PROPERTIES  
CYC 75  
PI WO 9710353 A1 19970320 (199718)\* EN 111p  
RW: AT BE CH DE DK EA ES FI FR GB GR IE IT KE LS LU MC MW NL OA PT SD  
SE SZ UG  
W: AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE FI GE HU IL IS JP KG KP  
KR KZ LC LK LE LS LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK TJ  
TM TR TT UA UZ VN  
AU 9670711 A 19970401 (199730)  
EP 865499 A1 19980923 (199842) EN  
R: AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE  
US 5929304 A 19990727 (199936)  
ADT WO 9710353 A1 WO 1996-US14730 19960913; AU 9670711 A AU 1996 70711

AB WO 9710353 A EPAB: 19970320  
A novel method for producing an enzymatically active **lysosomal**

enzyme (A) or modified **lysosomal** enzyme (B) in a transgenic plant, comprises: (a) growing the transgenic plant which has a **recombinant expression construct** comprising a nucleotide sequence encoding (A) or (B) and a promoter (preferably inducible promoter) that regulates expression of the nucleotide sequences so that (A) or (B) is expressed in the transgenic plant; and (b) recovering (A) or (B) from an organ of the transgenic plant; where (B) has the amino acid sequence of (A) with one or several amino acid substitutions, additions and/or deletions, and the organ is a leaf, stem, root, flower, fruit or seed. Also claimed are: (1) a **recombinant expression construct** (I) comprising a nucleotide sequence as above encoding (A) or (B); (2) a plant transformation vector comprising (I); (3) a **plant cell**, tissue or organ which has the recombinant expression vector of (2); (4) a transgenic plant or **plant cell** capable of producing (A) or (B) which contains a **recombinant expression construct** as in (1); and (5) (A) or (B) produced by growing a transgenic plant as in (4) and recovering the enzyme from an organ of the transgenic plant as above.

USE The plant expression system provides for post-translational modification and processing to produce a recombinant gene product ((A) or (B)) exhibiting enzymatic activity. (A) and (B) are useful for enzyme replacement therapy for therapeutic treatment of human and animal **lysosomal** storage diseases, e.g. Fabry, Farber and Gaucher diseases and Tay-Sachs, and industrial processes involving enzymatic substrate hydrolysis.

Dwg.0/21

L2 ANSWER 2 OF 2 USPATFULL

AN 1999:85655 USPATFULL

TI Production of **lysosomal** enzymes in plant-based expression systems

IN Radin, David N., Blacksburg, VA, United States

Cramer, Carole L., Blacksburg, VA, United States

Oishi, Karen K., Blacksburg, VA, United States

Weissenborn, Deborah L., Blacksburg, VA, United States

PA Cromptech Development Corporation, United States (U.S. corporation)

Virginia Tech Intellectual Properties, Inc., United States (U.S. corporation)

PI US 5929304 19990727

AI US 1996-713928 19960913 (8)

PRAI US 1995-3737 19950914 (60)

DT Utility

FS Granted

EXNAM Primary Examiner: Kemmerer, Elizabeth

LREP Pennie & Edmonds LLP

CLMN Number of Claims: 73

ECL Exemplary Claim: 1

DEWN 34 Drawing Figure(s); 29 Drawing Page(s)

LN.CNT 2625

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the production of enzymatically active recombinant human and animal **lysosomal** enzymes involving construction and expression of recombinant expression constructs comprising coding sequences of human or animal **lysosomal** enzymes in a plant expression system. The plant expression system provides for post translational modification and processing to produce a

... and human **lysosomal** enzymes produced in accordance with the invention may be used for a variety of purposes, including but not limited to enzyme

replacement therapy for the therapeutic treatment of human and animal  
**lysosomal** storage diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s l1 not l2  
L3 12 L1 NOT L2

=> dup rem l3  
PROCESSING COMPLETED FOR L3  
L4 12 DUP REM L3 (0 DUPLICATES REMOVED)

=> s l4 and promoter  
L5 12 L4 AND PROMOTER

=> d l5 bib abs 1-12

L5 ANSWER 1 OF 12 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD  
AN 2001-266173 [27] WPIDS  
DNN N2001-190325 DNC C2001-080631  
TI Novel **recombinant expression construct** for  
increasing yield potential in plants, comprises recombinant cell division  
enhancing sequence, and regulatory elements that provide for expression of  
sequence in **plant cell**.

DC C06 D16 P13

IN HABBEN, J E; SUN, Y

PA (PION-N) PIONEER HI-BRED INT INC

CYC 93

PI WO 2001023594 A2 20010405 (200127)\* EN 33p  
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ  
NL OA PT SD SE SL SZ TZ UG ZW  
W: AE AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ  
EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK  
LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG  
SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AU 2000076155 A 20010430 (200142)

ADT WO 2001023594 A2 WO 2000-US26405 20000926; AU 2000076155 A AU 2000-76155  
20000926

FDT AU 2000076155 A Based on WO 200123594

PRAI US 1999-156222P 19990927

AN 2001-266173 [27] WPIDS

AB WO 200123594 A UPAB: 20010518

NOVELTY - A **recombinant expression construct**

(I) for production of plants that have enhanced yield potential comprising  
a recombinant cell division enhancing nucleotide sequence (S), and  
regulatory elements that will provide for expression of (S) in a  
**plant cell**, is new.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for a  
transgenic plant (II) comprising a **plant cell** or its  
ancestor which has been transformed with (I).

USE - (I) is useful for increasing yield potential in a plant such as  
corn, barley, sorghum, soybeans, wheat, rice or Arabidopsis, by  
introducing (I) to a **plant cell**, where (I) is  
integrated into the **plant cell** (claimed). (I) is  
useful for enhancing stress tolerance (buffer female inflorescence),  
particularly high density and drought stresses, in plants at critical

DNN N2000 119891 DNC C2000 050167

TI Novel methods for the production of animal urokinase in plant-based

expression systems used for thrombolytic therapy and clearing catheters.

DC B04 C06 D16 P13

IN OISHI, K K; ZHOU, D

PA (CROP-N) CROPTECH DEV CORP

CYC 87

PI WO 2000000624 A1 20000106 (200014)\* EN 67p

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL  
OA PT SD SE SL SZ UG ZW

W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB  
GD GE HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD  
MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA  
UG US UZ VN YU ZA ZW

AU 9947147 A 20000117 (200026)

EP 1088081 A1 20010404 (200120) EN

R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

ADT WO 2000000624 A1 WO 1999-US14292 19990625; AU 9947147 A AU 1999-47147  
19990625; EP 1088081 A1 EP 1999-930655 19990625; WO 1999-US14292 19990625

FDT AU 9947147 A Based on WO 200000624; EP 1088081 A1 Based on WO 200000624

PRAI US 1998-90911 19980626; US 1998-91911 19980626

AN 2000-160680 [14] WPIDS

AB WO 200000624 A UPAB: 20000925

NOVELTY - Producing human or animal urokinase (UK) in plant expression systems, especially transgenic tobacco plants is new.

DETAILED DESCRIPTION - A novel method for producing a biologically active UK in a transgenic plant (especially tobacco) comprises:

(a) growing the transgenic plant which has a **recombinant expression construct** comprising a nucleotide sequence encoding the UK and a **promoter** that regulates expression of the nucleotide sequence so that the UK is expressed by the transgenic plant, and

(b) recovering the UK from an organ of the transgenic plant, e.g. leaf, stem, root, flower, seed or fruit.

INDEPENDENT CLAIMS are also included for the following:

(1) a **recombinant expression construct**, comprising a nucleotide sequence encoding UK and a **promoter** that regulates the expression of the nucleotide sequence in a **plant cell**;

(2) a plant transformation vector comprising the construct of (1);

(3) a **plant cell**, tissue or organ which contains the construct of (1);

(4) a transgenic plant or **plant cell** capable of producing a biologically active UK, comprising the construct of (1);

(5) a leaf, stem, root, flower or seed of the transgenic plant of (4), and

(6) a UK which is biologically active, and which is produced by the new method.

USE - The plant expression systems are used to produce human or animals urokinase (UK). The recombinant UK is used for the treatment of thrombolytic disorders, e.g. in patients suffering from an arterial or venous blockage caused by a fibrin clot, and also for clearing catheters, and for production of antibodies for diagnostic use.

ADVANTAGE - The production of urokinase (UK) in mammalian and yeast cells is inefficient. The new method is more efficient for the production of UK than previous art, and is also inexpensive, reliable and amenable to large scale production.

Dwg.0/10

Inventors: K. Oishi, D. Zhou, K. K. Oishi, D. Zhou, K. K. Oishi, D. Zhou

PA Valentis, Inc., Burlingame, CA, United States U.S. corporation

PI US 6235310

B1 20010522

AI US 1998-54769 19980403 (9)  
PRAI US 1997-88359 19970404 (60)  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Kishore, Gollamudi S.  
LREP McDonnell Boehnen Hulbert & Berghoff  
CLMN Number of Claims: 40  
ECL Exemplary Claim: 1  
DRWN 9 Drawing Figure(s); 9 Drawing Page(s)  
LN.CNT 1164

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and compositions are provided for the introduction of polyanionic molecules, in particular, nucleic acids, into mammalian cells using certain phosphatidyl ethanolamines as helper lipids in conjunction with various cationic lipids. In particular, cationic lipid-mediated transfection of mammalian cells is improved by the use of lipid carriers comprising DLPE or DiPPE and cationic lipids.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 4 OF 12 USPATFULL  
AN 2000:138504 USPATFULL  
TI Nucleotide sequences that encode phosphatidylinositol-3' kinase associated proteins and uses thereof  
IN Braselmann, Sylvia, San Francisco, CA, United States  
PA Onyx Pharmaceuticals, Inc., Richmond, CA, United States (U.S. corporation)  
PI US 6133419 20001017  
AI US 1997-942008 19971001 (8)  
PRAI US 1996-30103 19961101 (60)  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Achutamurthy, Ponnathapu; Assistant Examiner: Tung, Peter P.  
LREP Giotta, Gregory  
CLMN Number of Claims: 7  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 1939

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Identification, characterization and expression of nucleotides that encode phosphatidylinositol-3' kinase associated protein(s) that bind to the intermediate SH2 domain on the regulatory subunit of PI3K, p85, by the associated protein(s) C-terminal amino acids, and that exhibit a bromodomain are described, as well as methods of using such proteins for medical applications, including diagnosis and treatment cell growth disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 5 OF 12 USPATFULL  
AN 2000:9752 USPATFULL  
TI G-beta-gamma regulated phosphatidylinositol-3' kinase  
IN Stephens, Len, Sawston, United Kingdom  
Hawkins, Phillip Thomas, Sawston, United Kingdom  
Braselmann, Sylvia, San Francisco, CA, United States  
PA Onyx Pharmaceuticals, Inc., Richmond, CA, United States (U.S.

patented, Pat. No. US 5856132 which is a continuation in part of Ser. No. US 1996 672211, filed on 27 Jun 1996, now patented, Pat. No. US

5874273  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Achutamurthy, Ponnathapu; Assistant Examiner:  
Slobodyansky, Elizabeth  
LREP Pennie & Edmonds LLP, Giotta, Esq., Gregory  
CLMN Number of Claims: 25  
ECL Exemplary Claim: 1  
DRWN 20 Drawing Figure(s); 21 Drawing Page(s)  
LN.CNT 4917

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to the discovery, identification and characterization of nucleotides that encode the G protein regulated phosphatidylinositol-3' kinase, a heterodimeric enzyme which produces the intracellular messenger phosphatidylinositol (3,4,5)-triphosphate in response to activation of trimeric G protein-linked receptors. This novel protein, comprised of a catalytic subunit, p120, and a regulatory subunit, p101, is found in cells of hematopoietic origin and is involved in immune system responses which cause inflammation. The presence of p101 subunit is largely responsible for the dramatic stimulation of kinase activity in the presence of activated trimeric G proteins. The invention encompasses p101 and p120 nucleotides; host cell expression systems, p101 and p120 proteins, fusion proteins, polypeptides and peptides, antibodies to these proteins, transgenic animals that express a p101 or p120 transgene, or recombinant knock-out cells and animals that do not express the p101 or p120 gene, antagonists and agonists of the enzyme, and other compounds that modulate p101 or p120 gene expression or enzyme activity that can be used for diagnosis, drug screening, clinical trial monitoring, and/or the treatment of inflammatory disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 6 OF 12 USPATFULL  
AN 1999:113557 USPATFULL  
TI Methods of screening foods for nutraceuticals  
IN Ghai, Geetha, Murray Hill, NJ, United States  
Boyd, Charles, New Brunswick, NJ, United States  
Csiszar, Katalin, New Brunswick, NJ, United States  
Ho, Chi-Tang, East Brunswick, NJ, United States  
Rosen, Robert T., Pottersville, NJ, United States  
PA Rutgers, The State University of New Jersey, New Brunswick, NJ, United States (U.S. corporation)  
PI US 5955269 19990921  
AI US 1996-670826 19960620 (8)  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Myers, Carla J.  
LREP Pennie & Edmonds LLP  
CLMN Number of Claims: 43  
ECL Exemplary Claim: 1  
DRWN 1 Drawing Page(s)  
LN.CNT 2189

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to an assay system for screening nutraceuticals, i.e., foods or food substances that occur naturally, or that are produced during processing which are capable of modulating in a subject

The invention further provides methods for modifying the amount of nutraceuticals in raw and processed foods or food substances.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 7 OF 12 USPATFULL  
AN 1999:106321 USPATFULL  
TI Modulators of BRCA1 activity  
IN Rubinfeld, Bonnee, Danville, CA, United States  
Polakis, Paul G., Mill Valley, CA, United States  
Lingenfelter, Carol, Oakland, CA, United States  
Vuong, Terilyn T., Oakland, CA, United States  
PA Onyx Pharmaceuticals, Inc., Richmond, CA, United States (U.S. corporation)  
PI US 5948643 19990907  
AI US 1997-968751 19970813 (8)  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Hutzell, Paula K.; Assistant Examiner: Sun-Hoffman, Lin  
LREP Giotto, Gregory  
CLMN Number of Claims: 7  
ECL Exemplary Claim: 1  
DRWN 5 Drawing Figure(s); 7 Drawing Page(s)  
LN.CNT 2263

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions of matter consisting of a family of related nucleotide sequences that encode proteins, termed BRCA1 Modulator Proteins, that bind to the tumor suppressor gene product BRCA1, and methods of using the nucleotide sequences and the proteins encoded thereby, to diagnose and/or treat disease where the BRCA1 Modulator Proteins have an apparent molecular weight of 45-97 kdaltons and are characterized by having at least one leucine zipper domain, and optionally a zinc finger domain.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 8 OF 12 USPATFULL  
AN 1999:24494 USPATFULL  
TI G-beta-gamma regulated phosphatidylinositol-3' kinase  
IN Stephens, Len, Sawston, England  
Hawkins, Philip Thomas, Sawston, England  
PA Onyx Pharmaceuticals, Richmond, CA, United States (U.S. corporation)  
PI US 5874273 19990223  
AI US 1996-672211 19960627 (8)  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Patterson, Jr., Charles L.; Assistant Examiner: Slobodyonsky, Elizabeth  
LREP Pennie & Edmonds LLP  
CLMN Number of Claims: 33  
ECL Exemplary Claim: 1  
DRWN 15 Drawing Figure(s); 14 Drawing Page(s)  
LN.CNT 4148

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to the discovery, identification and characterization of nucleotides that encode the G protein regulated phosphatidylinositol-3' kinase, a heterodimeric enzyme which produces the intracellular messenger phosphatidylinositol (3,4,5)-triphosphate in response to activation of trimeric G protein-linked receptors. This

The present invention encompasses p101 and p120 nucleotides, host cell expression systems, p101 and p120 proteins, fusion proteins, polypeptides and

peptides, antibodies to these proteins, transgenic animals that express a p101 or p120 transgene, or recombinant knock-out cells and animals that do not express the p101 or p120 gene, antagonists and agonists of the enzyme, and other compounds that modulate p101 or p120 gene expression or enzyme activity that can be used for diagnosis, drug screening, clinical trial monitoring, and/or the treatment of inflammatory disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 9 OF 12 USPATFULL  
AN 1999:18940 USPATFULL  
TI G-beta-gamma regulated phosphatidylinositol-3' kinase  
IN Stephens, Len, Sawston, England  
Hawkins, Phillip Thomas, Sawston, England  
PA Onyx Pharmaceuticals, Richmond, CA, United States (U.S. corporation)  
PI US 5869271 19990209  
AI US 1997-972630 19971118 (8)  
RLI Division of Ser. No. US 1996-672211, filed on 27 Jun 1996  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Wax, Robert A.; Assistant Examiner: Slobodyansky, Elizabeth  
LREP Pennie & Edmonds LLP, Giotto, Gregory  
CLMN Number of Claims: 6  
ECL Exemplary Claim: 1  
DRWN 15 Drawing Figure(s); 14 Drawing Page(s)  
LN.CNT 3979

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to the discovery, identification and characterization of nucleotides that encode the G protein regulated phosphatidylinositol-3' kinase, a heterodimeric enzyme which produces the intracellular messenger phosphatidylinositol (3,4,5)-triphosphate in response to activation of trimeric G protein-linked receptors. This novel protein, comprised of a catalytic subunit, p120, and a regulatory subunit, p101, is found in cells of hematopoietic origin and is involved in immune system responses which cause inflammation. The presence of p101 subunit is largely responsible for the dramatic stimulation of kinase activity in the presence of activated trimeric G proteins. The invention encompasses p101 and p120 nucleotides, host cell expression systems, p101 and p120 proteins, fusion proteins, polypeptides and peptides, antibodies to these proteins, transgenic animals that express a p101 or p120 transgene, or recombinant knock-out cells and animals that do not express the p101 or p120 gene, antagonists and agonists of the enzyme, and other compounds that modulate p101 or p120 gene expression or enzyme activity that can be used for diagnosis, drug screening, clinical trial monitoring, and/or the treatment of inflammatory disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 10 OF 12 USPATFULL  
AN 1999:4855 USPATFULL  
TI G-beta-gamma regulated phosphatidylinositol-3' kinase  
IN Stephens, Len, Sawston, England  
Hawkins, Phillip Thomas, Sawston, England  
PA Onyx Pharmaceuticals, Richmond, CA, United States (U.S. corporation)

EXNAM Primary Examiner: Wax, Robert A.; Assistant Examiner: Slobodyansky, Elizabeth



LREP Pennie & Edmonds LLP, Giotta, Gregory  
CLMN Number of Claims: 13  
ECL Exemplary Claim: 1  
DRWN 15 Drawing Figure(s); 14 Drawing Page(s)  
LN.CNT 4012

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to the discovery, identification and characterization of nucleotides that encode the G protein regulated phosphatidylinositol-3' kinase, a heterodimeric enzyme which produces the intracellular messenger phosphatidylinositol (3,4,5)-triphosphate in response to activation of trimeric G protein-linked receptors. This novel protein, comprised of a catalytic subunit, p120, and a regulatory subunit, p101, is found in cells of hematopoietic origin and is involved in immune system responses which cause inflammation. The presence of p101 subunit is largely responsible for the dramatic stimulation of kinase activity in the presence of activated trimeric G proteins. The invention encompasses p101 and p120 nucleotides, host cell expression systems, p101 and p120 proteins, fusion proteins, polypeptides and peptides, antibodies to these proteins, transgenic animals that express a p101 or p120 transgene, or recombinant knock-out cells and animals that do not express the p101 or p120 gene, antagonists and agonists of the enzyme, and other compounds that modulate p101 or p120 gene expression or enzyme activity that can be used for diagnosis, drug screening, clinical trial monitoring, and/or the treatment of inflammatory disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 11 OF 12 USPATFULL  
AN 1999:1472 USPATFULL  
TI G-beta-gamma regulated phosphatidylinositol-3'kinase  
IN Stephens, Len, Cambridge, England  
Hawkins, Phillip Thomas, Cambridge, England  
PA Onyx Pharmaceuticals, Richmond, CA, United States (U.S. corporation)  
PI US 5856133 19990105  
AI US 1997-972631 19971118 (8)  
RLI Division of Ser. No. US 1996-672211, filed on 27 Jun 1996  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Wax, Robert A.; Assistant Examiner: Slobodyansky, Elizabeth  
LREP Pennie & Edmonds and Gregory Giotta LLP  
CLMN Number of Claims: 6  
ECL Exemplary Claim: 1  
DRWN 15 Drawing Figure(s); 14 Drawing Page(s)  
LN.CNT 3974

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to the discovery, identification and characterization of nucleotides that encode the G protein regulated phosphatidylinositol-3'kinase, a heterodimeric enzyme which produces the intracellular messenger phosphatidylinositol (3,4,5)-triphosphate in response to activation of trimeric G protein-linked receptors. This novel protein, comprised of a catalytic subunit, p120, and a regulatory subunit, p101, is found in cells of hematopoietic origin and is involved in immune system responses which cause inflammation. The presence of p101 subunit is largely responsible for the dramatic stimulation of kinase activity in the presence of activated trimeric G proteins. The

invention encompasses p101 and p120 nucleotides, host cell expression systems, p101 and p120 proteins, fusion proteins, polypeptides and peptides, antibodies to these proteins, transgenic animals that express a p101 or p120 transgene, or recombinant knock-out cells and animals that do not express the p101 or p120 gene, antagonists and agonists of the enzyme, and other compounds that modulate p101 or p120 gene expression or enzyme activity that can be used for diagnosis, drug screening,

clinical trial monitoring, and/or the treatment of inflammatory disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 12 OF 12 USPATFULL  
AN 1999:1471 USPATFULL  
TI G-beta-gamma regulated phosphatidylinositol-3' kinase  
IN Stephens, Len, Sawston, England  
Hawkins, Phillip Thomas, Sawston, England  
Braselmann, Sylvia, San Francisco, CA, United States  
PA Onyx Pharmaceuticals, Richmond, CA, United States (U.S. corporation)  
PI US 5856132 19990105  
AI US 1997-916917 19970815 (8)  
RLI Continuation-in-part of Ser. No. US 1996-672211, filed on 27 Jun 1996  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Wax, Robert A.; Assistant Examiner: Slobodyansky, Elizabeth  
LREP Pennie & Edmonds LLP, Giotta, Gregory  
CLMN Number of Claims: 32  
ECL Exemplary Claim: 1  
DRWN 22 Drawing Figure(s); 21 Drawing Page(s)  
LN.CNT 4569

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to the discovery, identification and characterization of nucleotides that encode the G protein regulated phosphatidylinositol-3' kinase, a heterodimeric enzyme which produces the intracellular messenger phosphatidylinositol (3,4,5)-triphosphate in response to activation of trimeric G protein-linked receptors. This novel protein, comprised of a catalytic subunit, p120, and a regulatory subunit, p101, is found in cells of hematopoietic origin and is involved in immune system responses which cause inflammation. The presence of p101 subunit is largely responsible for the dramatic stimulation of kinase activity in the presence of activated trimeric G proteins. The invention encompasses p101 and p120 nucleotides, host cell expression systems, p101 and p120 proteins, fusion proteins, polypeptides and peptides, antibodies to these proteins, transgenic animals that express a p101 or p120 transgene, or recombinant knock-out cells and animals that do not express the p101 or p120 gene, antagonists and agonists of the enzyme, and other compounds that modulate p101 or p120 gene expression or enzyme activity that can be used for diagnosis, drug screening, clinical trial monitoring, and/or the treatment of inflammatory disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.